Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

Abstract

Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer. Further investigations of topotecan in ovarian cancer, including first-line use and combination with other active agents, are indicated.